Becampanel (AMP397) is the first competitive AMPA antagonist and an antiepileptic agent.

Becampanel is negative in a mouse lymphoma tk assay, which includes a 24 h treatment without S9. A weak micronucleus induction in vitro is found at the highest concentrations tested in V79 cells with S9.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Becampanel is negative in the following in vivo studies, which includes the maximum tolerated doses of 320 mg/kg in mice and 2000 mg/kg in rats. Becampanel has no genotoxic potential in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Becampanel is negative in the following in vivo studies, which includes the maximum tolerated doses of 320 mg/kg in mice and 2000 mg/kg in rats. Becampanel has no genotoxic potential in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Suter W, et al. Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound. Mutat Res. 2002 Jul 25;518(2):181-94.  [Content Brief]